- Home
- PRLD vs SURG Comparison
PRLD vs SURG Comparison
Compare PRLD & SURG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- SURG
- Stock Information
- Founded
- PRLD 2016
- SURG 2006
- Country
- PRLD United States
- SURG United States
- Employees
- PRLD N/A
- SURG N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- SURG Advertising
- Sector
- PRLD Health Care
- SURG Consumer Discretionary
- Exchange
- PRLD Nasdaq
- SURG Nasdaq
- Market Cap
- PRLD 48.6M
- SURG 56.5M
- IPO Year
- PRLD 2020
- SURG N/A
- Fundamental
- Price
- PRLD $0.78
- SURG $3.24
- Analyst Decision
- PRLD Strong Buy
- SURG Strong Buy
- Analyst Count
- PRLD 2
- SURG 1
- Target Price
- PRLD $4.50
- SURG $9.00
- AVG Volume (30 Days)
- PRLD 221.0K
- SURG 108.3K
- Earning Date
- PRLD 08-11-2025
- SURG 08-12-2025
- Dividend Yield
- PRLD N/A
- SURG N/A
- EPS Growth
- PRLD N/A
- SURG N/A
- EPS
- PRLD N/A
- SURG N/A
- Revenue
- PRLD $7,000,000.00
- SURG $40,029,467.00
- Revenue This Year
- PRLD N/A
- SURG $57.76
- Revenue Next Year
- PRLD N/A
- SURG $112.61
- P/E Ratio
- PRLD N/A
- SURG N/A
- Revenue Growth
- PRLD N/A
- SURG N/A
- 52 Week Low
- PRLD $0.61
- SURG $1.05
- 52 Week High
- PRLD $6.80
- SURG $3.47
- Technical
- Relative Strength Index (RSI)
- PRLD 42.16
- SURG 61.40
- Support Level
- PRLD $0.77
- SURG $2.86
- Resistance Level
- PRLD $0.84
- SURG $3.31
- Average True Range (ATR)
- PRLD 0.07
- SURG 0.24
- MACD
- PRLD -0.02
- SURG 0.04
- Stochastic Oscillator
- PRLD 16.04
- SURG 80.49
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.